The moxifloxacin-clofazimine regimen increased the risk of significant QTc prolongation (HR 1.45) compared to the levofloxacin-clofazimine regimen in patients with rifampicin-resistant tuberculosis.
Does moxifloxacin/clofazimine increase QTc prolongation in patients with rifampicin-resistant tuberculosis?
The use of moxifloxacin and clofazimine in shorter regimens for rifampicin-resistant tuberculosis increases the risk of QTc prolongation, particularly in older patients and those with thyroid disease or cavitation.
Effect estimate: HR 1.45 (95% CI 1.01-2.07)
Absolute Event Rate: 48.4% vs 31.1%
p-value: p=0.044
Significant QTc prolongation risk increased with moxifloxacin/clofazimine. Thyroid disease, cavitation and age increased
Zhang et al. (Wed,) conducted a other in Rifampicin-resistant tuberculosis (n=410). Moxifloxacin and clofazimine (Mfx/Cfz) vs. Levofloxacin and clofazimine (Lfx/Cfz) was evaluated on Significant QTc prolongation (QTcF > 500 msec or increase > 60 msec) (HR 1.45, 95% CI 1.01-2.07, p=0.044). The moxifloxacin-clofazimine regimen increased the risk of significant QTc prolongation (HR 1.45) compared to the levofloxacin-clofazimine regimen in patients with rifampicin-resistant tuberculosis.